Activation of Tyrosine Kinases in Cancer

阅读量：

作者：

展开

摘要：

Receptor and nonreceptor tyrosine kinases (TKs) have emerged as clinically useful drug target molecules for treating certain types of . ()-TK is a receptor TK that is overexpressed or aberrantly activated in the most common , including and , prostate, and colon. Activation of the -TK enzyme results in , which drives signal pathways leading to and malignant progression. Randomized clinical trials of the -TK inhibitor have demonstrated clinical benefits in patients with advanced whose disease had previously progressed on - and docetaxel-based chemotherapy regimens. -is a constitutively activated nonreceptor TK enzyme found in the of Philadelphia -positive cells. STI571 () inhibits the -TK, blocks the growth of these cells, and induces . STI571 also inhibits other TKs, including the receptor TK , which is expressed in . As TK inhibitors become available for clinical use, new challenges include predicting which patients are most likely to respond to these targeted TK inhibitors. Additional clinical trials are needed to develop the full potential of receptor and nonreceptor TK inhibitors for treatment.

展开

关键词：

Humans Neoplasms Receptor, Epidermal Growth Factor Enzyme Inhibitors Apoptosis Gene Expression Regulation, Neoplastic Enzyme Activation Protein-Tyrosine Kinases Clinical Trials as Topic